Erik Mittra

Professor OHSU - Oregon Health & Science University

Dr. Mittra received his medical and graduate training through the MSTP (joint MD/PhD) program at Stony Brook University in New York in 2005. His master’s degree was in Anatomical Sciences, and his PhD in Biomedical Engineering. He subsequently completed a Nuclear Medicine residency and fellowship at Stanford University. He was faculty in Radiology at Stanford for 8 years, until moving to OHSU in 2018.

Dr. Mittra is interested in all aspects of Nuclear Medicine imaging, therapy, and research. This includes adult and pediatric general nuclear medicine imaging with gamma camera and SPECT, PET imaging for oncology, cardiac, and neurologic applications, as well as bone densitometry (DXA imaging). Targeted Radioisotope Therapies (TRT) are of particular interest; including various applications in oncology and he is a nationally-recognized expert in this area. His research interests are primarily focused on the clinical translation of novel radioisotopes for imaging and therapy. He is very involved with the Society of Nuclear Medicine and Molecular Imaging (SNMMI), the North American Neuroendocrine Tumor Society (NANETS), and is the current Medical Director of the Healing NET Foundation (HNF).

Seminars

Wednesday 22nd July 2026
The Roadmap from Phase I to Phase III: Standardizing Theranostic Protocols for Clinical Trial Success
3:30 pm
  • Developing adaptable protocols that ensure safe, reproducible procedures across early- and late-stage trials
  • Optimizing multidisciplinary workflows to support patient care, regulatory compliance, and staff training at every phase
  • Enabling consistent and high-quality data generation to accelerate trial progression and clinical adoption
Tuesday 21st July 2026
Radiopharmaceutical Recap: Landscape Updates, Major Milestones & Trends from Recent Years
9:00 am
  • Sharing how the radiopharmaceuticals field is rapidly advancing, with growing clinical data shaping our understanding of pharmacokinetics, efficacy, and safety
  • Examining where we stand and where we are heading across the landscape of therapeutic and diagnostic platforms
  • Exploring radiation dosimetry, regulatory considerations, and manufacturing – highlighting key learnings and emerging challenges
Erik Mittra